NHS RightCare is a programme committed to delivering the best care to patients, making the NHS’s money go as far as possible and improving patient outcomes. This programme helps to ensure the best possible care is delivered as efficiently as possible, which is right for patients and will help us have a sustainable NHS, now […]
Dementia Interactive Care Pathway Toolkit provides a one-stop shop resource for professionals working in dementia care. Following a partnership between academia, the NHS and the third sector, clinicians can now access a free toolkit containing a comprehensive roadmap and resources for the care of people with dementia.
by Sue Thomas Based on an initial idea from Faculty member Iracema Leroi, December has seen the Dementia Academy develop a new multi-level integrated dementia pathway toolkit that we hope will be a useful resource for everyone working in dementia care.
by Rachael Hansford The Neurology Academy is working with ACNR (Advances in Clinical Neuroscience & Rehabilitation) to produce an editorial e-newsletter for specialists in Australia and New Zealand in mid-January 2017. This collaboration will allow specialists in the region to freely access high quality, country specific, peer reviewed content via ACNR’s website.
by Dr James Fisher If you look after people with Parkinson’s disease (PD) you’ll know that sometimes medication administration in hospital is not as good as it could be. Things can get particularly challenging when patients are unable to take their usual tablets due to swallowing difficulties or being made nil by mouth (NBM). Missing […]
Dr Naomi Fox’s Parkinson’s medication and conversion calculator called ‘OPTIMAL’ has been launched and is now available for use. The new online tool, which will help professionals who are unfamiliar with Parkinson’s to better manage their patients in hospital, won the Parkinson’s Academy 2015 award for the best inter-module project.
The Parkinson’s Academy draws on a team of expert professionals with a rich blend of skills in treating and managing patients with Parkinson’s. Many of our speakers have a background in both clinical and research work, and so bring to bear both their practical experience as well as their knowledge about the evidence base for […]
Background Whether initial treatment for Parkinson’s disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson’s disease.